immunotherapy Archives | BioInformant

Webinar Case Study: ‘Companion Informatics’ to Automate Immunotherapy Manufacturing and Treatment

February 13, 2019 By Cade Hildreth, Founder & President Leave a Comment

L7 Informatics is honored to host a Free Webinar exploring a Case Study related to “‘Companion Informatics’ to Automate Immunotherapy Manufacturing and Treatment.”

Webinar: Companion Informatics’ to Automate Immunotherapy Manufacturing & Treatment

Genomics-driven precision medicine and regenerative medicine including cell and gene therapies require a new category of “companion informatics” software that automates and synchronizes complex data and process management. This software is applicable throughout the life-cycle of these complex therapeutics as they make their way from bench to clinical trials to bedside. [Read more…]

HemaCare Provides Starting Material for All Three FDA Approved Immunotherapies

November 16, 2018 By Cade Hildreth, Founder & President Leave a Comment

HemaCare Corporation (OTCMKTS: HEMA) is a long-standing leader in the customization and supply of human-derived biological products and services for biomedical research and cell therapy. Within the U.S. and internationally, the company is well-known for its network of FDA-registered, GMP/GTP-compliant collection centers where it collects human biological materials. Types of cellular materials collected and supplied by Hemacare include peripheral blood, bone marrow, and cord blood, each of which it isolates into primary cells types and can supply to customers in both fresh and frozen states. [Read more…]

Gradalis® Announces Initiation of Phase 3 Study of Vigil(TM) in Ewing’s sarcoma

August 28, 2018 By Cade Hildreth, Founder & President Leave a Comment

– The open-label trial will measure progression free survival of participants from date of randomization until first disease progression in the study –
– The trial will use product produced from Gradalis’ recently-upgraded cGMP Carrollton facility –

DALLAS, August 28, 2018 — Gradalis, Inc., a clinical-stage immunotherapy company developing investigational treatments for individuals suffering from multiple cancer indications, today announced the initiation of its Phase 3 clinical trial of Vigil for individuals with Ewing’s sarcoma using product produced from Gradalis’ recently upgraded current Good Manufacturing Practice (cGMP) Carrollton facility. [Read more…]

Fate Therapeutics Progress iPSC-Derived Cancer Immunotherapy Pipeline

August 13, 2017 By Cade Hildreth, Founder & President Leave a Comment

Founded in 2007 by Rudolf Jaenisch with backing from Arch Venture Partners, Fate Therapeutics’ corporate headquarters are in San Diego, California. It also has a subsidiary in Ottawa, Canada. Fate Therapeutics is an innovative biotechnology company developing novel stem cell modulators and biologic or small molecule compounds that guide cell fate. [Read more…]